Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled phase 3 study of dupilumab in chronic rhinosinusitis with bilateral nasal polyposis
MOH_2017-03-08_000190Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Sanofi. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on MOH_2017-03-08_000190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-08_000190.